SCHEMBL5045218

SCHEMBL5045218

CCO[C@H](C(=O)NCc1ccc(C#N)cc1)c1c(F)cc(-c2ccccc2O)cc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.38
SLC1A3 P43003 1/20 0.38
SLC1A2 P43004 1/20 0.38
DRD2 P14416 3/20 0.37
DRD3 P35462 1/20 0.37
PKM P14618 1/20 0.37
SCN5A Q14524 1/20 0.37
SCN9A Q15858 1/20 0.37
HIF1A Q16665 1/20 0.37
BACE1 P56817 2/20 0.36
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
F10 P00742 1/20 0.35
ELANE P08246 1/20 0.35
EPHX2 P34913 1/20 0.35
ALDH1A1 P00352 1/20 0.35
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
KDM1A O60341 1/20 0.34
HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5045213 1.00 CNR2 (0.38) CNR2SLC1A3SLC1A2DRD2DRD3
SCHEMBL5042022 0.90 CNR2 (0.40) CNR2SLC1A3SLC1A2DRD2DRD3
SCHEMBL5042027 0.90 CNR2 (0.40) CNR2SLC1A3SLC1A2DRD2DRD3
SCHEMBL5037967 0.89 SLC1A3 (0.42) CNR2SLC1A3SLC1A2PKMSCN5A
SCHEMBL5037965 0.89 SLC1A3 (0.42) CNR2SLC1A3SLC1A2PKMSCN5A
SCHEMBL5041754 0.88 CNR2 (0.37) CNR2SLC1A3SLC1A2DRD2DRD3
SCHEMBL5041755 0.88 CNR2 (0.37) CNR2SLC1A3SLC1A2DRD2DRD3
SCHEMBL5042129 0.86 EPHX2 (0.40) SLC1A3SLC1A2SCN5ASCN9AHIF1A
SCHEMBL5042131 0.86 EPHX2 (0.40) SLC1A3SLC1A2SCN5ASCN9AHIF1A
SCHEMBL5041460 0.85 KDM4E (0.42) DRD2DRD3HIF1AF10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 CNR2 372/4885SLC1A3 2652/4885SLC1A2 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.